Public Input Begins on EU Clinical Trials


From DCAT Value Chain Insights (VCI)

By Regulatory News posted 01-23-2015 12:11

  

The European Medicines Agency has launched the public consultation on how the transparency rules of the European Clinical Trial Regulation will be applied in the new clinical trial database. Stakeholders are invited to send their comments before February 18, 2015.

The European Clinical Trial Regulation aims to create an environment that is favorable to conducting clinical trials in the European Union (EU), including that that the rules for conducting clinical trials are consistent throughout the EU. It also transforms the level of information publicly available for each clinical trial carried out in the EU by requiring transparency on the authorization, conduct, and results of the trial. The regulation will apply to clinical trials that are registered once the regulation is in operation, which is to be not before May 28, 2016.

The key instrument to deal with clinical trials in a transparent way is the new clinical trial portal and database. It will be used for submission and maintenance of clinical trial applications and authorizations within the EU. It will serve as the source of public information on the clinical trial applications assessed and on all clinical trials conducted in the EU. According to the regulation, the EMA is responsible for the development and maintenance of the portal and database while the authorization and oversight of clinical trials will remain with the EU member states.

The public will be able to access extensive details of each trial, including the major characteristics of the trial, the start and end of recruitment, end date of the trial, and substantial modifications to the trial. These details will be made public as they occur starting with the decision on the trial. A summary of results and lay summary will be published 12 months after the end of the trial. For those trials included in a marketing authorization application in the EU, clinical study reports will also be published 30 days after the procedure for granting the marketing authorization has been completed or the application has been withdrawn.

The regulation requires that the clinical trial database shall be publicly available unless one or more of the following exceptions apply: protection of personal data; protection of commercially confidential information, in particular taking into account the marketing authorization status of the medicine, unless there is an overriding public interest; protection of confidential communication between EU member states in the preparation of their assessment; protection of the supervision of clinical trials by member states.

The document under consultation sets out proposals for the application of the transparency rules of the European Clinical Trial Regulation for stakeholders to review and comment on. "The proposals aim to balance the right of patients and the public to access extensive and timely information on clinical trials, and developers’ and researchers’ need to benefit from investments," said the EMA in the statement. "This will support the EU as a suitable location for innovative, cutting-edge research and development of medicines."

The public consultation refers only to the practical application of transparency rules for the clinical trial portal and database that is established within the European Clinical Trial Regulation. The European Clinical Trial Regulation is distinct from EMA’s policy on the publication of clinical data, which went into force as of January 2015). There are several important differences between the provisions of the European Clinical Trial Regulation and the EMA’s policy. Under the EMA’s policy, the agency proactively publishes the clinical study reports submitted as part of marketing-authorization applications for human medicines. This means that the policy applies to clinical reports of studies that are beyond the scope of the European Clinical Trial Regulation as it, for example, also includes clinical trials that are conducted outside the EU but that are submitted to the EMA for marketing authorization in Europe.

Source: EMA

0 comments
24 views


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription 

Permalink